×
  • Category
  • Type
  • Advanced

Q&A for Session #06: Understanding COVID-19 vaccines - safety and efficacy

Association between estimated cumulative vaccine antigen exposure through the first 23 months of life and non–vaccine-targeted infections from 24 through 47 months of age

Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial

Dissecting antigen processing and presentation routes in dermal vaccination strategies

The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial

Safety, tolerability and efficacy of intradermal rabies immunization with DebioJect™

India Injection Safety Implementation Project

Vaccine Innovation Lexicon

Assessing the potential cost-effectiveness of microneedle patches in childhood measles vaccination programs: The case for further research and development

Preferred Product Characteristics: Measles-Rubella Microarray Patch

Technet Conference Report: 2004

Technet Conference Report: 1999

Technet Conference Report 1998

Technet Conference Report: 1996

Technet Conference Report: 1994

Technet Conference Report: 1993

Technet Conference 1990: Report

A randomized trial of the effect of vaccine injection speed on acute pain in infants

The acceptability of three vaccine injections given to infants during a single clinic visit in South Africa

Innovation of a syringe needle auto-detaching device for clinicians